Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.37 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | HTR7 | P34969 | 6/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333978 | 0.91 | HTR1A (0.38) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2332796 | 0.91 | HTR1A (0.37) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| SCHEMBL2336452 | 0.88 | HTR1A (0.39) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| SCHEMBL12156834 | 0.87 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2334757 | 0.87 | HTR1A (0.38) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2334287 | 0.86 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| SCHEMBL12156828 | 0.86 | PIK3CD (0.48) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| SCHEMBL12156821 | 0.85 | HTR1A (0.37) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2332468 | 0.85 | PIK3CD (0.47) | HTR1ADRD2HTR2AHTR7SIGMAR1 | |
| Cadaverine Tartrate SCHEMBL2331481 | 0.85 | HTR1A (0.35) | HTR1ADRD2HTR2AHTR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048884-B2 | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2188268-B1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2188268-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100075976-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
| WO-2009029439-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075976-A1 | SUBSTITUTED PIPERAZINYL PYRAZINES AND PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | HTR1A 2/4885DRD2 319/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.